Growth factors in gliomas: Antisense and dominant negative mutant strategies

Journal of Neuro-Oncology

Volumn 35, Issue 3, 1997, Pages 275-285

  Campbell, Jeffrey W ^a   Pollack, Ian F ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NONE

Author keywords

Antisense; Dominant negative mutant; Gene therapy; Glioma; Growth factor; Signal transduction

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; COMPLEMENTARY DNA; FIBROBLAST GROWTH FACTOR RECEPTOR; GENE PRODUCT; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE C; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN;

CLINICAL TRIAL; GENE FUNCTION; GENE MUTATION; GENE REPRESSION; GLIOMA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; META ANALYSIS; PROTEIN ASSEMBLY; PROTEIN SYNTHESIS INHIBITION; REVIEW; RNA TRANSLATION; TRANSCRIPTION REGULATION;

ANIMALS; BRAIN NEOPLASMS; GENES, DOMINANT; GLIOMA; GROWTH SUBSTANCES; HUMANS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 0030853215     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005820701709     Document Type: Review

References (54)

1. Westermark B, Nister M: Molecular genetics of human glioma. Cur Opin Oncol 7: 220-225, 1995
2. Ohgaki H, Schauble B, Hausen A, von Ammon K, Kleihues P: Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch 427: 113-118, 1995
3. Westermark B, Heldin C-H, Nister M: Platelet-derived growth factor in human glioma. Glia 15: 257-263, 1995
4. Weinberg RA: How cancer arises. Scient Am 275(3): 62-70, 1996
5. Trojan J, Blossey BK, Johnson TR, Rudin SD, Tykocinski M, Ilan J, Ilan J: Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci USA 89: 4874-4878, 1992
6. Redekop GJ, Naus CC: Transfection with bFGF sense and antisense cDNA resulting in modification of malignant glioma growth. J Neurosurg 82: 83-90, 1995
7. Morrison RS, Yamaguchi F, Saya H, Bruner JM, Yahanda AM, Donehower LA, Berger M: Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. J Neuro-Onc 18: 207-216, 1994
8. Mishima K, Asai A, Sugiyama A, Miyagi Y, Kitanaka C, Kagaya S, Kirino T, Kuchino Y: Increased expression of schwannoma-derived growth factor (SDGF) mRNA in rat tumor cells: involvement of SDGF in the growth promotion of rat gliomas. Int J Cancer 66: 352-357, 1996
9. Plate KH, Risau W: Angiogenesis in malignant gliomas. Glia 15: 339-347, 1995
10. Heldin C-H, Westermark B : Growth factors as transforming proteins. Eur J Biochem 184: 487-496, 1989
11. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT: Response of low-passage human malignant gliomas in vitro to stimulation and selective inhibition of growth factor-mediated pathways. J Neurosurg 75: 284-293, 1991
12. Westphal M, Hamel D, Zirkel D, Herrmann HD, Bilzer T, Reifenberger G, Schober R, Wechsler W, Albert FK, Behnke J, Fries G, Keller D, Messing M, Stasiecki P: Epidermal growth factor receptor expression in human malignant gliomas: in vitro and in vivo effects of application of monoclonal antibodies to the epidermal growth factor receptor. Recent Results Cancer Res 135: 171-184, 1994
13. Belikova AM, Zarytova VF, Grineva NI: Synthesis of ribonucleosides and diribonucleoside phosphates containing 2-chloroethylamine and nitrogen mustard residues. Tetrahedron Lett 37: 3557-3562, 1967
14. Zamecnik PC, Stephenson ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci (USA) 75: 280-284, 1978
15. Rothenberg M, Johnson G, Laughlin C, Green I, Cradock J, Sarver N, Cohen JS: Oligodeoxynucleotides as anti-sense inhibitors of gene expression: therapeutic implications. J Natl Cancer Inst 81: 1539-1544, 1989
16. Stein CA, Cheng YC: Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 261: 1004-1012, 1993
17. Stein CA: Anti-sense oligodeoxynucleotides-promises and pitfalls. Leukemia 6: 967-974, 1992
18. Whitesell L, Geselowitz D, Chavany C, Fahmy B, Walbridge S, Alger JR, Neckers LM: Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application with the central nervous system. Proc Natl Acad Sci USA 90: 4665-4669, 1993
19. Dolnick BJ: Antisense agents in cancer research and therapeutics. Cancer Invest 9: 185-194, 1991
20. Gura T: Antisense has growing pains. Science 270: 575-577, 1995
21. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM : CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549, 1995
22. Trojan J , Johnson TR , Rudin SD , Ilan J , Tykocinski ML , Ilan J: Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259: 94-96, 1993
23. Resnicoff M, Li W, Basak S, Herlyn D, Baserga R, Rubin R: Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense m RNA. Cancer Immunol Immunother 42: 64-68, 1996
24. Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, Rubin R: Rat glioblastoma cells expressing an antisense RNA to insulin-like growth factor-1 (IGF-1) are nontumorigenic and induce regression of wild-type tumors. Cancer Res 54: 2218-2222, 1994
25. Sheppard D: Dominant negative mutants: tools for the study of protein function in vitro and in vivo. Am J Respir Cell Mol Biol 11: 1-6, 1994
26. Herskowitz I: Functional inactivation of genes by dominant negative mutations. Nature 329: 219-222, 1987
27. Liu J-P, Baker J, Perkins AS, Robertson EJ, Efstratladis A: Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75: 59-72, 1993
28. Baserga R : The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55: 249-252, 1995
29. Prager D, Li H-L, Asa S, Melmed S: Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl A cad Sci USA 91: 2181-2185, 1994
30. Ambrose D, Resnicoff M, Coppola D, Sell C, Miura M, Jameson S, Baserga R, Rubin R: Growth regulation of human glioblastoma T98G cells by insulin-like growth factor-1 and its receptor. J Cell Phys 159: 92-100, 1994
31. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R : Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res 54: 4848-4850, 1994
32. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, Zoltick P, Baserga R : The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 55: 2463-2469, 1995
33. Resnicoff M, Burgaud J-L, Rotman HL, Abraham D, Baserga R : Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res 55: 3739-3741, 1995
34. Guha A, Dashner K, Black PM, Wagner JA, Stiles CD : Ex-pression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 60: 168-173, 1995
35. Potapova O, Fakhrai H, Mercola D : Growth factor PDGF-B/v-sis confers a tumorigenic phenotype to human tumor cells bearing PDGF receptors but not to cells devoid of receptors: evidence for an autocrine, but not a paracrine, mechanism. Int J Cancer 66: 669-677, 1996
36. Shamah SM, Stiles CD, Guha A: Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol Cell Biol 13: 7203-7212, 1993
37. Nitta T, Sato K : Specific inhibition of c-sis protein synthesis and cell proliferation with antisense oligodeoxynucleotides in human glioma cells. Neurosurg 34: 309-315, 1994
38. Murphy PR, Sato Y, Knee RS: Phosphorothioate antisense oligonucleotides against basic fibroblast growth factor inhibit anchorage-dependent and anchorage-independent growth of a malignant glioblastoma cell line. Mol Endo 6: 877-884, 1992
39. Morrison RS: Suppression of basic fibroblast growth factor expression by antisense oligodeoxynucleotides inhibits the growth of transformed human astrocytes. J Biol Chem 266: 728-734, 1991
40. Behl C, Winkler J, Bogdahn U, Meixensberger J, Schigensiepen K-H, Brysch W: Autocrine growth regulation in neuroectodermal tumors as detected with oligodeoxynucleotide antisense molecules. Neurosurg 33: 679-684, 1993
41. Gately S, Tsanaclis AM, Takano S, Klagsbrun M, Brem S: Cells transfected with the basic fibroblast growth factor gene fused to a signal sequence are invasive in vitro and in situ in the brain. Neurosurg 36: 780-788, 1995
42. Morrison RS, Giordano S, Yamaguchi F, Hendrickson S, Berger MS, Palczewski K: Basic fibroblast growth factor expression is required for clonogenic growth of human glioma cells. J Neurosci Res 34: 502-509, 1993
43. Yamada SM, Bruner JM, Berger MS, Morrison RS: Expression of fibroblast growth factor receptors (FGFRs) mRNA in human astrocytomas. No To Shinkei 48: 363-370, 1996
44. Yamada SM, Yamaguchi F, Brown R, Berger MS, Morrison RS: Suppression of fibroblast growth factor receptor expression by antisense oligonucleotides inhibits the growth of human astrocytoma cells, 11th International Conference on Brain Tumor Research and Therapy, 1995
45. Laird AD, Brown PI, Fausto N: Inhibition of tumor growth in liver epithelial cells transfected with a transforming growth factor α antisense gene. Cancer Res 54: 4224-4232, 1994
46. Yung WK, Taylor S, Shi X, Steck PA : Modulation of transforming growth factor-alpha (TGF-α) autocrine growth regulation by antisense oligonucleotides in glioma cells. Proc Am Assoc Cancer Res 34: 524, 1993
47. 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 78: 944-951, 1993
48. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE : Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA 93: 2909-2914, 1996
49. Kimura H: Schwannoma-derived growth factor must be transported into the nucleus to exert its mitogenic activity. Proc Natl Acad Sci USA 90: 2165-2169, 1993
50. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A : Glioblastoma growth inhibited in vivo by a dominant-negative ELK-1 mutant. Nature 367: 576-579, 1994
51. Saleh M, Stacker SA, Wilks AF: Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56: 393-401, 1996
52. Pollack IF, Kawecki S, Lazo JS: B locking of glioma prolifer-ation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. J Neurosurg 84: 1024-1032, 1996
53. Baltuch GH, Dooley NP, Rostworowski KM, Villemure J-G, Yong VW: Protein kinase C isoform α overexpression in C6 glioma cells and its role in cell proliferation. J Neuroonc 24: 241-250, 1995
54. Ahmad S, Mineta T, Martuza RL, Glazer RI: Antisense expression of protein kinase Ca inhibits growth and tumorigenicity of human glioblastoma cells. Neurosurg 35: 904-909, 1994